A Phase 1 interventional study of BI 1015550 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 11 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 1, and was the 16th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Belgium, Finland and 6 more countries
Ages 40+
By country, each count listing its studies:
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 18 interventional studies, 212 across the 16 observational. Of the 31 that completed or were terminated, 26 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
2 of the studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF.
The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 tablets of 6 milligram (mg) of BI 101550 (total: 18 mg) were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily (bid). Treatment period was 4 weeks for patients entered after approval of a global protocol amendment 3 at 12 Feb 2019 or 12 weeks for those entered before approval.
Drug: BI 1015550
3 tablets of Placebo, matching in size and weight to BI 1015550 6 milligram (mg) tablet, were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment 3 at 12 Feb 2019 or 12 weeks for those entered before approval.
Drug: Placebo
3 tablets of 6 milligram (mg) of BI 101550 (total: 18 mg) were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily (bid).
Also known as: Nerandomilast, JASCAYD®
3 tablets of Placebo, matching in size and weight to BI 1015550 6 milligram (mg) tablet, were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily.
Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment
The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). All AEs which occurred through the treatment phase and throughout the residual effect period (REP) were considered as on treatment. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment at 12 Feb 2019 or 12 weeks for those entered before approval.
Time frame: From first dose until last dose of treatment period (duration depends on the time a patient entered the trial) + 7 days of REP or until patient's trial termination date, whichever occurred earlier, up to 35 or 91 days.
Area Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 1
Area under the concentration-time curve (AUCτ,1) of the BI 1015550 in plasma over a uniform dosing interval τ after administration of the first dose on Day 1.
Time frame: On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Maximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1
Maximum measured concentration (Cmax) of the BI 1015550 in plasma on Day 1.
Time frame: On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Area Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14
Area under the concentration-time curve (AUCτ,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.
Time frame: On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Maximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14
Maximum measured concentration (Cmax,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.
Time frame: On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
This randomized, double-blind, placebo-controlled, multiple rising dose trial was to test safety and tolerability of BI 1015550 in patients with idiopathic pulmonary fibrosis under dosage of 18mg and 24mg twice daily (bid). Dose escalation was stopped after the 18 mg bid dose group as predefined stopping criteria was met.
| Milestone | Placebo | 18 mg BI 1015550 |
|---|---|---|
| Started | 5 | 10 |
| Completed | 5 | 8 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Inconvenience to frequent study visits | 0 | 1 |
The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). All AEs which occurred through the treatment phase and throughout the residual effect period (REP) were considered as on treatment. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment at 12 Feb 2019 or 12 weeks for those entered before approval.
| Percentage of participants | 18 mg BI 1015550 | Placebo |
|---|---|---|
| Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment | 90.0 | 60.0 |
Area under the concentration-time curve (AUCτ,1) of the BI 1015550 in plasma over a uniform dosing interval τ after administration of the first dose on Day 1.
| nanomol (nmol) * hours (h) / Litre (L) | 18 mg BI 1015550 |
|---|---|
| Area Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 1 | 1990 ± 18.2 |
Maximum measured concentration (Cmax) of the BI 1015550 in plasma on Day 1.
| nanomol (nmol) / Litre (L) | 18 mg BI 1015550 |
|---|---|
| Maximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1 | 277 ± 23.1 |
Area under the concentration-time curve (AUCτ,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.
| nanomol (nmol) * hours (h) / Litre (L) | 18 mg BI 1015550 |
|---|---|
| Area Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14 | 3720 ± 49.5 |
Maximum measured concentration (Cmax,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.
| nanomol (nmol) / Litre (L) | 18 mg BI 1015550 |
|---|---|
| Maximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14 | 460 ± 41.7 |
Collected over From first dose until last dose of treatment period (duration depends on the time a patient entered the trial) + 7 days of REP or until patient's trial termination date, whichever occurred earlier, up to 35 or 91 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| 18 mg BI 1015550 | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Event | Placebo | 18 mg BI 1015550 |
|---|---|---|
| Anal fistulaGastrointestinal disorders | 0/5 | 1/10 |
| Anal incontinenceGastrointestinal disorders | 0/5 | 1/10 |
| Event | Placebo | 18 mg BI 1015550 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/5 | 4/10 |
| NasopharyngitisInfections and infestations | 0/5 | 4/10 |
| FlatulenceGastrointestinal disorders | 1/5 | 3/10 |
| Occult blood positiveInvestigations | 1/5 | 3/10 |
| Vision blurredEye disorders | 1/5 | 0/10 |
| FatigueGeneral disorders | 1/5 | 2/10 |
| PharyngitisInfections and infestations | 1/5 | 0/10 |
| Respiratory tract infectionInfections and infestations | 1/5 | 0/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/5 | 2/10 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 0/5 | 2/10 |
Treated set (TS): This patient set included all patients who received at least one dose of study drug. It was used for the analysis of safety, demographic data, and baseline characteristics.
| Age, Continuous(Years) | Placebo | 18 mg BI 1015550 | Total |
|---|---|---|---|
| Mean | 70.2 ± 3.3 | 69.5 ± 10.1 | 69.7 ± 8.3 |
| Sex: Female, Male(Participants) | Placebo | 18 mg BI 1015550 | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 4 | 9 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 18 mg BI 1015550 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 10 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 18 mg BI 1015550 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 10 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Jul 2019, 15 months.
Results were first posted in Nov 2025, 6 years 4 months after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 15 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast
Idiopathic Pulmonary Fibrosis →